Anti-Mouse CD8α Antibody (YTS169.4)
Based on 1 Customer Validation
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8+ T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection. Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).
For research use only. We do not sell to patients.
- Purity : 98.99%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Rat IgG2b kappa
Recommend Isotype Controls
Species Reactivity
Mouse
In Vivo
Anti-Mouse CD8α Antibody (YTS169.4) (2 mg; i.v.; twice (3 days and 1 day prior to α-GalCer injection)), when co-administered alongside rat anti-mouse CD4 (YTS191.1) antibody, reduces intrahepatic CD8+ T cell populations to <1.5% of preinjection levels without affecting NKT or NK cell counts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Biozzi AB/H (H-2^dq1)[1]
-
Dosage:250 μg (i.p. administration; splenocyte depletion; CREAE pre-acute, acute active, post-acute remission treatment); 75 μg (i.c. administration; CNS CREAE testing)
-
Administration:i.p.; single injection (day 9 p.i., day 12 p.i., acute disease onset, day 27 p.i.); i.c.; single injection (day 12 p.i.)
-
Result:Rapidly depleted CD8+ splenocytes to 0.1% within 24 hours post 250 μg i.p.
injection, remained at 0.1% at 7 days, and recovered to 1.2% at 27 days.
Failed to inhibit CREAE development, with 7/8 mice developing clinical CREAE (mean score 2.6, onset day 17.9) after day 9 p.i.
pre-acute treatment, 13/14 mice developing clinical CREAE (mean score 3.0) after day 12 p.i.
pre-acute treatment, and 6/6 mice developing clinical CREAE (mean score 2.8, onset day 16.5 ) after day 12 p.i.
i.c. treatment.
Failed to prevent CREAE relapse, with 6/8 mice relapsing (onset day 40.5) after day 12 p.i.
pre-acute treatment, 8/9 mice relapsing (mean score 2.9, onset day 37.8) after day 27 p.i.
post-acute remission treatment.
-
Animal Model:HBV transgenic lineage 1.3.32, C57BL/6 × BALB/c F1 hybrid (male, 8-10 weeks old, matched for serum HBeAg levels)[2]
-
Dosage:2 mg
-
Administration:i.v.; twice (3 days and 1 day prior to α-GalCer injection)
-
Result:Reduced intrahepatic CD8+ T cell populations to <1.5% of preinjection levels.
Left NKT cell and NK cell numbers unaffected.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay, Research in vivo
Verified Bioactivity
-
Loaded Anti-Mouse CD8α Antibody (YTS169.4) on AHC2 biosensor, can bind Mouse CD8α with an affinity constant of 1.08E-09 M as determined in BLI assay.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CD8a Antibody (YTS169.4)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. O'Neill JK, et al. Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies. J Neuroimmunol. 1993;45(1-2):1-14. [Content Brief]
[2]. Kakimi K, et al. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med. 2000;192(7):921-930. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse CD8α Antibody (YTS169.4) Related Classifications
HY-P991112 Related Classifications
Powered by Bioz